Seeking Alpha

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Nasdaq

Milestone Pharmaceuticals Announces PDUFA Date for CARDAMYST™ Nasal Spray and Plans for Phase 3 Study in AFib-RVR

The PDUFA date for CARDAMYST™ is set for March 27, 2025, indicating a lengthy approval timeline that could delay commercialization and revenue generation for the company. The reliance on the FDA's ...
Seeking Alpha

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil ...